Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China.

Background: Unresectable hepatocellular carcinoma (uHCC) remains a major clinical challenge with limited effective therapeutic options. Triple therapy combining interventional treatments, donafenib, and anti-PD-1 monoclonal antibodies has shown promise in recent studies, but real-world data remain limited.

Objective: To evaluate the real-world efficacy and safety of triple therapy with interventional treatment, donafenib, and anti-PD-1 monoclonal antibodies in patients with uHCC.

Prognostic and immunotherapeutic significance of NCAPD2 in pan-cancer and its role in hepatocellular carcinoma progression via the AKT/GSK-3β signaling pathway.

Present studies indicated that NCAPD2 (Non-SMC condensin I complex subunit D2) has emerged as an essential participant of condensin I involved in the mitotic chromosome assembly and dissociation. However, its comprehensive role in pan-cancer and its underlying mechanisms remain underexplored. This study systematically analyzed NCAPD2's prognostic significance, functional mechanisms, and immune infiltration correlations in pan-cancer, with a focus on hepatocellular carcinoma (HCC).

FCGR2A contributes to M2 macrophages polarization in HCC through IL-4/JAK/STAT6 axis.

The most common subtype of primary liver cancer is hepatocellular carcinoma (HCC), which accounts for about 90 % of primary liver cancers. Tumor microenvironment (TME) plays important roles in HCC development. TME coexists and interacts with various immune cells.

circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR-338-5p/IL-7 pathway.

Hepatocellular cancer is one of the most serious types of cancer in the world, with high incidence and mortality rates. Most HCC patients with long-term chemotherapy develop chemoresistance, leading to a poor prognosis. However, the underlying mechanism of circRNAs in HCC chemoresistance remains unclear.